JP4894439B2 - Blood glucose measuring device - Google Patents
Blood glucose measuring device Download PDFInfo
- Publication number
- JP4894439B2 JP4894439B2 JP2006265690A JP2006265690A JP4894439B2 JP 4894439 B2 JP4894439 B2 JP 4894439B2 JP 2006265690 A JP2006265690 A JP 2006265690A JP 2006265690 A JP2006265690 A JP 2006265690A JP 4894439 B2 JP4894439 B2 JP 4894439B2
- Authority
- JP
- Japan
- Prior art keywords
- level
- blood glucose
- measurement
- subject
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims description 156
- 210000004369 blood Anatomy 0.000 title claims description 156
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 144
- 239000008103 glucose Substances 0.000 title claims description 144
- 238000005259 measurement Methods 0.000 claims description 121
- 230000005540 biological transmission Effects 0.000 claims description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 230000006870 function Effects 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 19
- 208000013016 Hypoglycemia Diseases 0.000 description 17
- 230000002218 hypoglycaemic effect Effects 0.000 description 17
- 208000003443 Unconsciousness Diseases 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 11
- 230000002490 cerebral effect Effects 0.000 description 9
- 230000009471 action Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010009866 Cold sweat Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Landscapes
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Description
本発明は、血糖測定装置に関する。 The present invention relates to a blood glucose measurement device.
糖尿病治療では、食事療法又は運動療法を行っても高血糖が続く場合、経口血糖降下剤及びインスリン製剤等の薬物を投与する薬物治療が行われる場合がある。例えば、特許文献１では、血糖値を無侵襲に連続モニタリングまたは間欠測定し、その値に応じて定量的にインシュリン量を最適化し、自動的にインシュリンを体内に注入するシステムを開示している。 In the treatment of diabetes, when hyperglycemia continues even after dietary therapy or exercise therapy, drug treatment in which drugs such as oral hypoglycemic agents and insulin preparations are administered may be performed. For example, Patent Document 1 discloses a system in which blood glucose level is continuously monitored or intermittently measured non-invasively, the amount of insulin is optimized quantitatively according to the value, and insulin is automatically injected into the body.
しかしながら、ヒトの血糖値は、食事の量、食事の間隔、運動量及び労働量などの日常生活に応じて刻々と変動している。これに伴い、すい臓からのインスリンの分泌量も、その時の血糖に応じて調節されている。つまり、単純に被測定者の血糖値を測定するだけでは、的確なインシュリン等の薬物の投与量を決定することは困難である。 However, human blood glucose levels are constantly changing according to daily life such as the amount of meal, the interval between meals, the amount of exercise, and the amount of work. Along with this, the amount of insulin secreted from the pancreas is also adjusted according to the blood glucose at that time. That is, it is difficult to determine an appropriate dose of a drug such as insulin by simply measuring the blood glucose level of the subject.
特許文献２は、近距離無線通信機能を有する血糖値測定部、制御部、インシュリンポンプおよび運動量測定部を含む装着システムを使用する血糖管理システムを開示している。つまり、血糖値測定部にて血糖値を測定するだけではなく、運動量測定部にて被測定者の運動量も測定する。そして、これらの結果を参照することにより、投与するインシュリン量を決定する血糖管理システムである。しかしながら、特許文献２に開示される血糖管理システムであっても、食事の量及び食事の間隔等をモニタリングすることは困難である。 Patent Document 2 discloses a blood glucose management system that uses a mounting system including a blood glucose level measurement unit, a control unit, an insulin pump, and an exercise amount measurement unit having a short-range wireless communication function. That is, not only the blood glucose level is measured by the blood glucose level measurement unit, but also the exercise amount of the measurement subject is measured by the exercise amount measurement unit. And it is a blood glucose management system which determines the amount of insulin to administer by referring these results. However, even with the blood sugar management system disclosed in Patent Document 2, it is difficult to monitor the amount of meal, the interval between meals, and the like.
以上のことから、糖尿病患者に投与した薬物によるインスリン等の薬物の分泌、インスリン等の薬物の作用、注射したインスリン等の薬物の効果を、日常生活の血糖の微妙な変動に対応して臨機応変に調節することには技術的な限界がある。よって、上記特許文献１又は特許文献２のようなインスリン等の薬物を投与する機能を備える血糖測定装置では、投与するインスリン等の薬物量を誤って多く設定してしまう場合がある。投与する薬物量が多くなれば、その効果も強くなるので、予想以上に血糖値が下がってしまい低血糖になる場合がある。 Based on the above, the secretion of drugs such as insulin by drugs administered to diabetic patients, the action of drugs such as insulin, and the effects of drugs such as injected insulin change in response to subtle fluctuations in blood glucose in daily life. There are technical limitations in adjusting to this. Therefore, in a blood glucose measurement device having a function of administering a drug such as insulin as in Patent Document 1 or Patent Document 2, a large amount of drug such as insulin to be administered may be set erroneously. As the amount of the drug to be administered increases, the effect becomes stronger, so that the blood sugar level may be lowered more than expected and hypoglycemia may occur.
低血糖とは、薬物治療で使用する薬の効力が効きすぎることにより、血糖が下がりすぎる状態をいう。その症状としては、まず、空腹感、体のだるさ、ふらふら感、冷や汗、手のふるえ、動悸、不安感及び頭痛等の症状が現れる（自律神経症状、警告症状ともいう）。さらに血糖値が下がると、眠気、脱力、めまい、集中力の低下、混乱、見当まちがい、元気がなくなる、イライラ、ぎこちない動作、普段と違う言動及び発語障害等の症状が現れる（中枢神経症状）。もっと血糖値が下がると、意識障害、けいれん及び昏睡等の症状が現れる（大脳機能低下症状）。 Hypoglycemia refers to a state in which blood sugar is too low due to the effect of drugs used in drug treatment being too effective. Symptoms include hunger, dullness, fluffiness, cold sweat, hand tremor, palpitation, anxiety, and headaches (also called autonomic symptoms and warning symptoms). If the blood glucose level further decreases, symptoms such as drowsiness, weakness, dizziness, poor concentration, confusion, misplacement, disappointment, irritation, awkward movements, unusual speech and speech disorders, etc. (central nervous system symptoms) . If the blood glucose level further decreases, symptoms such as disturbance of consciousness, seizures, and coma appear (cerebral dysfunction symptoms).
何よりも、低血糖において最も恐ろしいところは、その症状が自覚できない場合があることである。いわゆる無自覚低血糖とよばれるものである。無自覚低血糖は、突然意識障害、けいれん及び昏睡等の大脳機能低下症状が現れる。このため、例えば、運転中に無自覚低血糖による大脳機能低下症状が現れた場合は非常に危険である。また、周囲に助ける人がいない場所で、無自覚低血糖による大脳機能低下症状が現れた場合も非常に危険である。 Above all, the most frightening part of hypoglycemia is that the symptoms may not be noticed. This is called unconscious hypoglycemia. Unconscious hypoglycemia suddenly causes cerebral hypofunction symptoms such as consciousness disturbance, seizures, and coma. For this reason, for example, when a cerebral hypofunction due to unconscious hypoglycemia appears during driving, it is very dangerous. It is also very dangerous if cerebral dysfunction due to unconscious hypoglycemia appears in a place where there is no helping person nearby.
本発明は、無自覚低血糖による大脳機能低下症状が現れる前の事前予防機能、及び、事後対策機能を備えた血糖測定装置を提供することを課題とする。 An object of the present invention is to provide a blood glucose measurement device having a pre-prevention function before a symptom of hypocerebral function due to unconscious hypoglycemia and a post-measure function.
本発明は、
被測定者の血糖値を連続若しくは間欠的に測定する装置であって、
被測定者の血糖値を連続若しくは間欠的で測定する測定部と、
被測定者の第１危険レベル血糖値、並びに、被測定者の第２危険レベル血糖値を含む被測定者情報を記憶する記憶部と、
前記測定部で測定された血糖値と、前記記憶部に記憶された被測定者情報を参照することによって、被測定者が健常、第１危険レベル若しくは第２危険レベルであることを判定する判定部と、
前記判定部にて被測定者が第１危険レベルであると判定された時に、被測定者に第１危険レベルであることを通知する通知手段：及び
前記判定部にて被測定者が第２危険レベルであると判定された時に、被測定者が第２危険レベルであるという情報を発信する発信手段を備え、
前記判定部は、
（１）前記測定部で測定された血糖値が、前記記憶部から参照された第１危険レベルの血糖値に達した時に、被測定者が第１危険レベルである判定し、
（２）さらに、前記測定部で測定された血糖値が、第１危険レベル血糖値に達した後から一度も第１危険レベル血糖値以上に復帰せず、かつ前記記憶部から参照された第２危険レベルの血糖値に達した時に、被測定者が第２危険レベルであると判定する
ことを特徴とする血糖測定装置に関する。
The present invention
A device for continuously or intermittently measuring a subject's blood sugar level,
A measurement unit that continuously or intermittently measures the blood glucose level of the measurement subject;
A storage unit that stores measurement subject information including the first danger level blood glucose level of the measurement subject and the second danger level blood glucose level of the measurement subject;
Determination to determine whether the subject is healthy, at the first risk level, or at the second risk level by referring to the blood glucose level measured by the measurement unit and the subject information stored in the storage unit And
When the determination unit determines that the measured person is at the first danger level, a notification means for notifying the measured person that the measured person is at the first danger level; A transmission means for transmitting information that the measured person is at the second danger level when the danger level is determined to be;
The determination unit
(1) When the blood glucose level measured by the measurement unit reaches the blood glucose level of the first risk level referenced from the storage unit, the person to be measured is determined to be the first risk level;
(2) Furthermore, the blood glucose level measured by the measurement unit never returns to the first risk level blood glucose level or more once after reaching the first risk level blood glucose level, and is referred to from the storage unit. The present invention relates to a blood glucose measurement device characterized in that when a blood glucose level at a second risk level is reached, the measurement subject is determined to be at a second risk level.
本発明の血糖測定装置は、無自覚低血糖による大脳機能低下症状が現れる前の事前予防機能を備えている。このため、被測定者は、ブドウ糖を摂取することによる無自覚低血糖による大脳機能低下症状の事前予防を行うことができる。さらに、上記の事前予防が遅れた場合であって、周りに助ける人がいない場所で無自覚低血糖による大脳機能低下症状が現れたとしても、本発明の血糖測定装置は事前予防機能を備えているため、例えば、医療機関、及び／又は、被測定者の血縁者等に通知することができる。 The blood glucose measurement device of the present invention has a pre-prevention function before symptoms of reduced cerebral function due to unconscious hypoglycemia appear. For this reason, the person to be measured can prevent in advance cerebral hypofunction due to unconscious hypoglycemia by ingesting glucose. Furthermore, even if the above-mentioned pre-prevention is delayed, and a cerebral function lowering symptom due to unconscious hypoglycemia appears in a place where there is no helper around, the blood glucose measurement device of the present invention has a pre-prevention function Therefore, for example, it is possible to notify a medical institution and / or a relative of the subject.
以下、本発明を本発明の図面を参照して説明する。 Hereinafter, the present invention will be described with reference to the drawings of the present invention.
図１は、本発明の血液測定装置の機能ブロック図である。本発明の血液測定装置は、被測定者の血糖値を連続若しくは間欠的に測定する装置をいう。その構成は、被測定者の血糖値を連続若しくは間欠的で測定する測定部１と、被測定者情報を記憶する記憶部２と、被測定者が健常、第１危険レベル若しくは第２危険レベルであることを判定する判定部３と、被測定者に第１危険レベルであることを通知する通知手段４、及び、被測定者が第２危険レベルであるという情報を発信する発信手段５を備える。本発明における被測定者とは、本発明の血糖測定装置の測定対象となる人をいい、主に糖尿病患者が挙げられる。 FIG. 1 is a functional block diagram of the blood measuring apparatus of the present invention. The blood measurement device of the present invention refers to a device that continuously or intermittently measures the blood glucose level of a measurement subject. The configuration includes a measurement unit 1 that continuously or intermittently measures the blood glucose level of the measurement subject, a storage unit 2 that stores measurement subject information, and whether the measurement subject is healthy, the first risk level or the second risk level. A determination unit 3 that determines that the subject is a first danger level, a notification unit 4 that notifies the measurement subject that the subject is at the first danger level, and a transmission unit 5 that sends information that the subject is at the second danger level. Prepare. The person to be measured in the present invention refers to a person to be measured by the blood glucose measurement device of the present invention, and mainly includes diabetic patients.
本発明の血液測定装置は、被測定者の血糖値を連続若しくは間欠的で測定する測定部１を備える。本発明における測定部１は、採用する測定系によりその概念は変動的であるが、少なくとも測定を行うための手段、及び、測定された結果から血糖値に変換する手段を含む。例えば、光学的に血糖値を測定する場合は、光を測定対象に照射する手段、測定対象を透過若しくは反射された光を受光する手段、及び、照射した光と受光した光の変化を血糖値に変換する手段等を含む。 The blood measurement apparatus of the present invention includes a measurement unit 1 that continuously or intermittently measures a blood glucose level of a measurement subject. The measuring unit 1 in the present invention, although the concept is variable depending on the measurement system employed, includes at least means for performing measurement and means for converting the measured result into a blood glucose level. For example, when the blood glucose level is optically measured, the means for irradiating the measurement target with light, the means for receiving the light transmitted or reflected through the measurement target, and the change in the irradiated light and the received light are the blood glucose level. Including means for converting to
測定は、被測定者の血糖値を常に管理できる観点から連続的に測定することが最も好ましい。但し、必ずしも連続的に測定する必要はなく、測定時間間隔が短いものであれば間欠的であっても十分である。測定時間の間隔としては、例えば、５分以内、好ましくは３分以内である。測定時間間隔が５分よりも長いと、後述する判定部３における判定、及び、当該判定部３にて判定された結果による作動する通知手段４並びに発信手段５の作動が遅れるからである。これらの測定は全自動で行われる。 Most preferably, the measurement is continuously performed from the viewpoint of always managing the blood glucose level of the measurement subject. However, it is not always necessary to measure continuously, and intermittent measurement is sufficient if the measurement time interval is short. The measurement time interval is, for example, within 5 minutes, preferably within 3 minutes. This is because if the measurement time interval is longer than 5 minutes, the determination in the determination unit 3 to be described later and the operation of the notification unit 4 and the transmission unit 5 that operate according to the determination result of the determination unit 3 are delayed. These measurements are performed fully automatically.
また、連続的若しくは間欠的に測定するためには、被測定者は常に本発明の血糖測定装置を携帯する必要がある。そして、測定部１は、被測定者の血糖値を測定するために、被測定者の皮膚等に接触する構造を含む。例えば、リストバンド型、ヘッドギア型、腕時計型、ネックレス型、指輪型、イヤリング型、及び、貼付膜型等の構造が挙げられるが、本発明これらの構造に限定されるものではない。 Further, in order to measure continuously or intermittently, the person to be measured must always carry the blood glucose measuring device of the present invention. And the measurement part 1 contains the structure which contacts a to-be-measured person's skin etc., in order to measure a to-be-measured person's blood glucose level. For example, structures such as a wristband type, a headgear type, a wristwatch type, a necklace type, a ring type, an earring type, and an adhesive film type are exemplified, but the present invention is not limited to these structures.
また、測定は、侵襲又は非侵襲で測定することができるが、非侵襲で測定することが好ましい。また、測定は基本的には血液中におけるグルコース量若しくは濃度を対象とするが、汗、尿及び／又は唾液等の血液以外の非侵襲で採取しうる生体液を対象とし、間接的に血液中におけるグルコース量若しくは濃度に変換もよい。特に採取が容易である観点から汗が好ましい。 Further, the measurement can be performed invasively or non-invasively, but preferably non-invasively. Measurements are basically targeted for the amount or concentration of glucose in the blood, but for biological fluids that can be collected non-invasively other than blood, such as sweat, urine and / or saliva, and indirectly in the blood. It is also possible to convert to glucose amount or concentration. In particular, sweat is preferable from the viewpoint of easy collection.
上記の測定系の例としては、例えば、特開２００６−０００６５９号公報にはミリ波を被測定者に照射し、反射係数等からグルコース濃度を測定する系が開示されている。また、特開平０９−０６８５２３号公報には唾液を採取し、その粘度から間接的に血糖値に変換する系が開示されている。さらに、特表平０９−５０３９２４号公報には発汗した汗に近赤外線を照射し、その測定結果から間接的に血糖値に変換する系が開示されている。これらの系の中でも、直接的に血糖値を測定することができる観点から、ミリ波を被測定者に照射し、グルコース濃度を測定する系を用いることが好ましいが、本発明はこれらに限定されるものではない。 As an example of the above measurement system, for example, Japanese Patent Laid-Open No. 2006-000659 discloses a system that irradiates a measurement subject with a millimeter wave and measures a glucose concentration from a reflection coefficient or the like. Japanese Patent Application Laid-Open No. 09-068523 discloses a system that collects saliva and indirectly converts it into a blood sugar level from its viscosity. Furthermore, Japanese National Publication No. 09-503924 discloses a system that irradiates perspired sweat with near infrared rays and indirectly converts it to a blood glucose level from the measurement result. Among these systems, it is preferable to use a system that measures the glucose concentration by irradiating the subject with millimeter waves from the viewpoint of directly measuring the blood glucose level, but the present invention is not limited thereto. It is not something.
本発明の血糖測定装置は、被測定者情報を記憶する記憶部２を備える。本発明において、被測定者情報とは、少なくとも第１危険レベル血糖値及び第２危険レベル血糖値を含む。 The blood glucose measurement device of the present invention includes a storage unit 2 that stores measurement subject information. In the present invention, the person-to-be-measured information includes at least the first danger level blood sugar level and the second danger level blood sugar level.
上記第１危険レベル血糖値とは、被測定者が無自覚低血糖でない場合、空腹感、体のだるさ、ふらふら感、冷や汗、手のふるえ、動悸、不安感及び頭痛からなる症状群のいずれか１つ、つまり、自律神経症状（警告症状）が現れはじめる血糖値をいう。したがって、第１危険レベル血糖値は、被測定者の血糖値の通常範囲（日差変動範囲）よりも低い値となる。もちろん、無自覚低血糖の場合はこれらの症状は現れない。第１危険レベル血糖値は、被測定者の食生活、運動量及び体質等により個人差があるが、通常は５０〜７０程度である。 The blood sugar level of the first risk level is any one of symptom groups consisting of hunger, dullness, fluffiness, cold sweat, hand tremor, palpitation, anxiety and headache when the subject is not unconscious hypoglycemia. That is, the blood sugar level at which autonomic symptoms (warning symptoms) begin to appear. Therefore, the first risk level blood glucose level is lower than the normal range (daily fluctuation range) of the blood glucose level of the measurement subject. Of course, in the case of unconscious hypoglycemia, these symptoms do not appear. The first risk level blood glucose level varies from individual to individual depending on the dietary life, exercise amount, constitution, etc. of the subject, but is usually about 50-70.
一方、第２危険レベル血糖値とは、被測定者が意識障害、けいれん及び昏睡からなる症状群のいずれか１つ、つまり、大脳機能低下症状が現れはじめる血糖値をいう。したがって、第２危険レベル血糖値は、第１危険レベル血糖値よりも低い値となる。第２危険レベル血糖値は、第１危険レベル血糖値と同様、被測定者の食生活、運動量及び体質等により個人差があるが、通常は３０〜５０程度である。 On the other hand, the second risk level blood glucose level refers to a blood glucose level at which the measured person begins to show any one of symptom groups consisting of disturbance of consciousness, convulsions, and coma, that is, symptoms of reduced cerebral function. Therefore, the second risk level blood glucose level is lower than the first risk level blood glucose level. The second risk level blood glucose level varies from individual to individual depending on the diet, exercise amount, constitution, etc. of the person to be measured, like the first risk level blood glucose level, but is usually about 30 to 50.
上記第１危険レベル血糖値及び第２危険レベル血糖値は、医師が被測定者の臨床検査等による結果から適宜判断する。判断された１危険レベル血糖値及び第２危険レベル血糖値は、本発明の血糖測定装置に搭載する入力部６から入力する。入力された第１危険レベル血糖値及び第２危険レベル血糖値は、記憶部２に記憶される。例えば、図１に示すように、１危険レベル血糖値記憶メモリ２１及び第２危険レベル血糖値記憶メモリ２２にそれぞれ記憶する。もちろん、ひとつのメモリに第１危険レベル血糖値及び第２危険レベル血糖値を記憶してもよい。
The first risk level blood glucose level and the second risk level blood glucose level are appropriately determined by a doctor based on the result of a clinical test or the like of the measurement subject. The determined 1st risk level blood glucose level and 2nd risk level blood glucose level are input from the input part 6 mounted in the blood glucose measurement device of the present invention. The input first risk level blood glucose level and second risk level blood glucose level are stored in the storage unit 2. For example, as shown in FIG. 1, the data is stored in a first risk level blood sugar level storage memory 21 and a second risk level blood sugar
本発明の血糖測定装置は、被測定者が健常、第１危険レベル若しくは第２危険レベルであることを判定する判定部３を備える。判定部３による判定は、前記測定部１で測定された血糖値と、前記記憶部２に記憶された被測定者情報を参照することによって実施される。そして、被測定者が健常状態であると判定した場合は、そのまま装置の測定状態を維持する。被測定者が第１危険レベルであると判定した場合、判定部３は後述する通知手段４を作動させる。被測定者が第２危険レベルであると判定した場合、判定部３は後述する発信手段５を作動させる。 The blood glucose measurement device of the present invention includes a determination unit 3 that determines that the measurement subject is healthy and is at the first risk level or the second risk level. The determination by the determination unit 3 is performed by referring to the blood glucose level measured by the measurement unit 1 and the measured person information stored in the storage unit 2. And when it determines with a to-be-measured person being in a healthy state, the measurement state of an apparatus is maintained as it is. When it is determined that the measurement subject is at the first danger level, the determination unit 3 activates a notification unit 4 described later. When it determines with a to-be-measured person being the 2nd danger level, the determination part 3 operates the transmission means 5 mentioned later.
本発明において、通知手段４とは、上記判定部３にて被測定者が第１危険レベルであると判定した場合に作動する手段をいう。その機構は、主にアラーム、発光、発色、電気的刺激、及び、バイブレーション等が挙げられる。特に携帯電話等で親しまれるアラーム及びバイブレーションが好ましいが、本発明は必ずしもこれらに限定されるものではない。通知手段４が作動した場合、被測定者の血糖値は、第１危険レベル血糖値よりも低い値であるため、被測定者が無自覚低血糖である場合であったとしても、迅速にブドウ糖等を摂取することにより通常の血糖値領域まで回復することができる。ブドウ糖等の摂取は、例えば、ブドウ糖５〜１０ｇ又は砂糖１０〜２０ｇ若しくはそれに相当する糖質の入った食品など挙げられる。特にα−グルコシダーゼ阻害薬を他の傾向血糖投下薬を併用している場合は砂糖では効果がない場合があるため、ブドウ糖が好ましい。いずれにせよ、担当医師の指示に従った適切な対応をすればよい。 In the present invention, the notification means 4 refers to means that operates when the determination unit 3 determines that the measurement subject is at the first danger level. The mechanism mainly includes alarm, light emission, color development, electrical stimulation, and vibration. In particular, alarms and vibrations familiar to mobile phones and the like are preferable, but the present invention is not necessarily limited to these. When the notification means 4 is activated, the blood glucose level of the measurement subject is lower than the first risk level blood glucose level, so even if the measurement subject has unconscious hypoglycemia, glucose etc. Can be recovered to the normal blood sugar level region. Examples of the intake of glucose and the like include foods containing 5 to 10 g of glucose or 10 to 20 g of sugar or a sugar corresponding thereto. In particular, when an α-glucosidase inhibitor is used in combination with another tendency to drop blood sugar, sugar is not effective, and glucose is preferable. In any case, an appropriate response may be made in accordance with the instructions of the doctor in charge.
本発明において、発信手段５とは、上記判定部３にて被測定者が第２危険レベルであると判定した場合に作動する手段をいう。その機構は、主に電話回線、ＬＡＮ回線、インターネット、及び、光ブロードバンド等が挙げられる。特に、送信先の人と直接会話ができる電話回線が好ましいが、本発明は必ずしもこれらに限定されるものではない。また、発信先は、被測定者の血縁者、担当医師、及び／又は、サポートセンターの従業員であればよい。以下、これらの人々を血縁者等と称す。発信手段５が作動した場合、被測定者の血糖値は、第２危険レベル血糖値よりも低い値であるため、もはや被測定者自身で対応することが困難となる。さらに被測定者の周囲に被測定者を救助する人がいない場合であったとしても、血縁者等又は救急機関は発信手段５から発信された情報を基に被測定者の救助に向かうことができる。また、被測定者の周囲に被測定者を救助する人がいる場合であっても、補助的にその役割を果たすことができるのはいうまでもない。この際、被測定者の現在位置を正確に把握できる観点から、本発明の血糖測定装置は、さらにＧＰＳ機能を搭載することが好ましい。 In the present invention, the transmission means 5 refers to means that operates when the determination unit 3 determines that the person to be measured is at the second danger level. The mechanism mainly includes a telephone line, a LAN line, the Internet, and optical broadband. In particular, a telephone line capable of directly talking with a destination person is preferable, but the present invention is not necessarily limited thereto. Further, the destination may be a relative of the person being measured, a doctor in charge, and / or an employee of the support center. Hereinafter, these people are called relatives. When the transmission means 5 is activated, the blood glucose level of the person to be measured is lower than the blood sugar level at the second danger level, so it is no longer easy for the person to be measured to cope with the blood sugar level. Furthermore, even if there is no person who rescues the subject around the subject, the relative or the emergency organization may go to rescue the subject based on the information sent from the sending means 5. it can. Further, it goes without saying that even if there is a person who rescues the subject around the subject, the role can be supplementarily played. At this time, from the viewpoint of accurately grasping the current position of the person to be measured, the blood glucose measurement device of the present invention preferably further includes a GPS function.
また、一般に被測定者が無自覚低血糖による大脳機能低下症状が現れた場合であって、当該被測定者の周囲に被測定者を救助する人がいる場合、当該被測定者を救助する人は、被測定者が携帯している患者カードに記載される文書に従って、被測定者にブドウ糖等を摂取させることにより救助する。しかしながら、被測定者を救助する人には低血糖に関する知識がない人もいるため、被測定者が患者カードを携帯していることすら気づかない場合も多い。 Also, in general, when the subject has cerebral dysfunction due to unconscious hypoglycemia, and there is a person who rescues the subject around the subject, the person who rescues the subject is The patient is rescued by ingesting glucose or the like according to the document written on the patient card carried by the patient. However, since there are people who have no knowledge about hypoglycemia among those who rescue the subject, there are many cases where the subject does not even realize that the subject is carrying a patient card.
したがって、本発明の血糖測定装置は、発信手段５による血縁者等と直接会話できる会話機能を搭載することが好ましい。当該会話機能により、救助する人は血縁者等の指示に従って救助することができる。 Therefore, it is preferable that the blood glucose measurement device of the present invention is equipped with a conversation function that enables direct conversation with relatives by the transmission means 5. With the conversation function, the person who rescues can rescue according to the instructions of the relatives.
上述の会話機能を搭載する態様の他にも、本発明の血糖測定装置には、被測定者を救助する人に対して音声にて通知する音声通知機能を搭載してもよい。救助する人は、当該音声通知機能の指示に従って被測定者を救助することができる。 In addition to the above-described mode in which the conversation function is installed, the blood glucose measurement device of the present invention may be equipped with a voice notification function for notifying a person who rescues the person to be measured by voice. The rescuer can rescue the subject in accordance with the instructions of the voice notification function.
また、上記音声通知機能は、救助する人に本発明の血糖測定装置の表示部７を含む部品の位置を知らせた上で、患者カードと同様の記載を表示した表示部７を見るように指示する機能であってもよい。これにより、音声通知機能により通知する情報が短くなる。つまり、救助する人が当該音声通知機能により通知する情報を途中から聞いたとしても、当該通知が最初に戻るまでの時間が短いために、救助する人は迅速に救助することができる。
In addition, the voice notification function notifies the rescuer of the position of the parts including the
本発明の通知手段４及び発信手段５は、被測定者の血糖状態によりそれぞれ独立に作動する態様であるため、想定される被測定者のあらゆる事態に対して対応することができる。例えば、通知手段４が作動した場合であって、被測定者がブドウ糖等の摂取により対応することができた場合、被測定者の血糖値は通常範囲（日差変動範囲）に回復する。もはや、被測定者の血糖値は第２危険レベル血糖値には至らないため、発信手段５が作動することはない。これにより、被測定者の血縁者等への通信頻度が抑えられるため、被測定者の血縁者等の行動が制限される頻度も少なくなる。また、被測定者が当該被測定者の血縁者等に対して申し訳ないという心理状態に陥ることがないため、被測定者の精神的ストレスも低減される。 Since the notification means 4 and the transmission means 5 of this invention are the aspects which operate | move independently according to a to-be-measured person's blood glucose state, they can respond to all the situations of the to-be-measured person. For example, when the notification means 4 is activated and the subject can respond by ingesting glucose or the like, the blood glucose level of the subject is restored to the normal range (daily fluctuation range). Since the blood glucose level of the person to be measured no longer reaches the second dangerous level blood glucose level, the transmission means 5 does not operate. As a result, the frequency of communication of the person to be measured with the related person or the like is suppressed, and the frequency with which the action of the person to be measured is related is also reduced. Moreover, since the measurement subject does not fall into a psychological state that he / she is sorry for the relative of the measurement subject, the mental stress of the measurement subject is also reduced.
一方で、例えば、上記判定部３にて被測定者が第１危険レベルであると判定したとしても、通知手段４の態様がアラームである場合、街中などの騒音がある場所では被測定者がアラームに気づかない場合がある。また、通知手段４の態様がバイブレーションである場合も、被測定者が歩行していれば、バイブレーションに気づかない場合がある。このような場合、被測定者は、ブドウ糖等の摂取等の対応が遅れてしまうことがある。特に、無自覚低血糖の場合、血糖値の低下速度が速いため、被測定者がブドウ糖等の摂取等の対応をする前に、大脳機能低下症状が現れてしまうこともある。上述したように、大脳機能低下症状が現れるともはや被測定者自身で対応することができなくなるが、発信手段５の機能によりこの問題は解決される。 On the other hand, for example, even if it is determined by the determination unit 3 that the measured person is at the first danger level, if the mode of the notification means 4 is an alarm, the measured person is located in a place with noise such as in the city. You may not notice the alarm. In addition, even when the mode of the notification unit 4 is vibration, there is a case where the vibration is not noticed if the person to be measured is walking. In such a case, the measurement subject may be delayed in taking glucose and the like. In particular, in the case of unconscious hypoglycemia, since the blood glucose level decreases rapidly, symptoms of reduced cerebral function may appear before the subject measures to take glucose or the like. As described above, when the cerebral function lowering symptom appears, the person to be measured can no longer cope with it, but the function of the transmitting means 5 solves this problem.
一般に、非侵襲かつ連続若しくは間欠的に測定する血糖測定装置は、例えば、リストバンド型、ヘッドギア型、腕時計型、ネックレス型、指輪型、イヤリング型、及び、貼付膜型等の被測定者に被測定者の皮膚等に接触する構造を備える。すると、被測定者によっては、このような皮膚等に接触する構造の帯同を嫌う人も存在する。 In general, blood glucose measuring devices that measure non-invasively and continuously or intermittently are applied to a subject such as a wristband type, a headgear type, a watch type, a necklace type, a ring type, an earring type, and a patch membrane type. It has a structure that comes into contact with the skin of the measurer. Then, depending on the person to be measured, there is a person who dislikes the band of the structure that contacts the skin or the like.
しかしながら、本発明の血糖測定装置のような付加価値のある装置であれば、被測定者は、このような皮膚等に接触する構造を帯同してもよいという心理状態になるであろう。また、本発明の血糖測定装置は、上述したように、被測定者自身で対応可能な場合と、そうでない場合により、それぞれ対応した機構を作動する。このため、例えば、不用意に被測定者の血縁者等に被測定者が危険な状態であるという情報を送信することがない。したがって、被測定者の血縁者等の行動が制限される頻度が少なくなり、被測定者も周囲に迷惑をかけて申し訳ないという精神的ストレスが低減される。 However, if it is a device with added value such as the blood glucose measurement device of the present invention, the person to be measured will be in a psychological state that he / she may share such a structure in contact with the skin or the like. In addition, as described above, the blood glucose measurement device of the present invention operates corresponding mechanisms depending on whether or not the measurement subject can cope with the subject himself / herself. For this reason, for example, information that the measurement subject is in a dangerous state is not inadvertently transmitted to the relative of the measurement subject. Therefore, the frequency at which the actions of the relatives of the measurement subject are restricted is reduced, and the mental stress that the measurement subject also annoys the surroundings is reduced.
以下、本発明の血糖測定装置のシステム制御について、図２に示すフロー図を用いて説明する。 Hereinafter, system control of the blood glucose measurement device of the present invention will be described with reference to the flowchart shown in FIG.
（通常血糖測定モード）
測定開始当初は、被測定者は健常であるものとして、本発明の血糖測定装置は通常測定モードＳ０１にある。そして、連続的若しくは間欠的に被測定者の血糖値を測定する。測定された血糖値の情報は、判定部３に送信される。判定部３は、被測定者の状態が第１危険レベルであるか否かを判定する（図２のＳ０２）。判定部３による被測定者の状態が第１危険レベル状態であるか否かは、測定血糖値が第１危険レベル血糖値以下になったか否かで判定される。もし、測定血糖値が第１危険レベル血糖値以下になったと判定された場合（例えば、図３の矢印Ａ）、当該判定部３は通知手段４を作動するべく信号を送信する（図２のＳ０３）。その後、本発明の血糖測定装置は第１危険レベル血糖測定モードＳ０４に移行する。
(Normal blood glucose measurement mode)
At the beginning of the measurement, the blood glucose measuring device of the present invention is in the normal measurement mode S01, assuming that the measurement subject is healthy. Then, the blood glucose level of the measurement subject is measured continuously or intermittently. Information on the measured blood sugar level is transmitted to the determination unit 3. The determination unit 3 determines whether or not the state of the measurement subject is the first danger level (S02 in FIG. 2). Whether or not the state of the person to be measured by the determination unit 3 is in the first danger level state is determined by whether or not the measured blood glucose level is equal to or lower than the first danger level blood glucose level. If it is determined that the measured blood glucose level is equal to or lower than the first risk level blood glucose level (eg, arrow A in FIG. 3), the determination unit 3 transmits a signal to activate the notification means 4 (in FIG. 2). S03). Thereafter, the blood glucose measurement device of the present invention proceeds to the first danger level blood glucose measurement mode S04.
一方、被測定者の血糖値が通常範囲（日差変動範囲）にある限り、本発明の血糖測定装置は通常測定モードＳ０１にある。 On the other hand, as long as the blood glucose level of the measurement subject is in the normal range (daily fluctuation range), the blood glucose measurement device of the present invention is in the normal measurement mode S01.
（第１危険レベル血糖測定モード）
第１危険レベル血糖測定モードＳ０４において、判定部３は、まず被測定者の状態が健常状態までに復帰したか否かを判定する（図２のＳ０５）。健常状態まで復帰したか否かは、少なくとも測定血糖値が第１危険レベル血糖値よりも大きい値まで復帰すれば十分である。好ましくは、通常範囲（日差変動範囲）までの復帰であるが、本発明はこれらに限定されるものではない。つまり、被測定者が、当該被測定者自身が第１危険レベルであることを認識した上で、例えば、ブドウ糖の摂取を行うなどして対応したものと、判定部３が判定したことになる。判定部３によって、被測定者が健常状態までに復帰したものと判定された場合、本発明の血糖測定装置は通常血糖測定モードＳ０１に移行する。
(First risk level blood glucose measurement mode)
In the first risk level blood glucose measurement mode S04, the determination unit 3 first determines whether or not the state of the subject has returned to the normal state (S05 in FIG. 2). Whether or not it has returned to a healthy state is sufficient if at least the measured blood glucose level returns to a value greater than the first danger level blood glucose level. Preferably, it is a return to the normal range (daily fluctuation range), but the present invention is not limited to these. That is, the determination unit 3 determines that the person to be measured recognizes that the person himself / herself is at the first danger level and responds, for example, by ingesting glucose. . When the determination unit 3 determines that the person to be measured has returned to the normal state, the blood glucose measurement device of the present invention shifts to the normal blood glucose measurement mode S01.
一方、判定部３にて測定血糖値が健常状態まで復帰しない場合、判定部３は続けて被測定者の状態が第２危険レベル状態であるか否かを判定する（図２のＳ０６）。判定部３による被測定者の状態が第２危険レベル状態であるか否かは、測定血糖値が第２危険レベル血糖値以下になったか否かで判定される。もし、測定血糖値が第２危険レベル血糖値以下になったと判定された場合（例えば、図３の矢印Ｂ）、当該判定部３は発信手段５を作動させるべく信号を送信する（図２のＳ０７）。その後、本発明の血糖測定装置は第２危険レベル血糖測定モードＳ０８に移行する。 On the other hand, if the measured blood glucose level does not return to the normal state in the determination unit 3, the determination unit 3 continues to determine whether or not the measurement subject is in the second danger level state (S06 in FIG. 2). Whether or not the state of the person to be measured by the determination unit 3 is in the second danger level state is determined by whether or not the measured blood sugar level is equal to or lower than the second danger level blood sugar level. If it is determined that the measured blood glucose level is equal to or lower than the second risk level blood glucose level (for example, arrow B in FIG. 3), the determination unit 3 transmits a signal to activate the transmission means 5 (in FIG. 2). S07). Thereafter, the blood glucose measurement device of the present invention proceeds to the second danger level blood glucose measurement mode S08.
また、もし、判定部３が被測定者の状態が第２危険レベル状態でもない、つまり、第１危険レベル状態が維持されていると判定した場合、本発明の血糖測定装置は第１危険レベル血糖測定モードＳ０４を維持する。長時間、例えば、３０分以上第１危険レベル血糖測定モードを維持するようであれば、再度判定部３から通知手段４を作動させるべく信号を送信してもよいが、これに限定されるものではない。 Further, if the determination unit 3 determines that the state of the person being measured is not the second danger level state, that is, the first danger level state is maintained, the blood glucose measurement device of the present invention has the first danger level. The blood glucose measurement mode S04 is maintained. If the first danger level blood glucose measurement mode is to be maintained for a long time, for example, 30 minutes or more, a signal may be transmitted from the determination unit 3 to operate the notification means 4 again, but the present invention is not limited to this. is not.
（第２危険レベル血糖測定モード）
第２危険レベル血糖測定モードＳ０８において、判定部３は、まず被測定者の状態が健常状態までに復帰したか否かを判定する（図２のＳ０９）。健常状態まで復帰したか否かは、少なくとも測定血糖値が第１危険レベル血糖値よりも大きい値まで復帰すれば十分である。好ましくは、通常範囲（日差変動範囲）までの復帰であるが、本発明はこれらに限定されるものではない。つまり、大脳機能低下症状の疑いのある被測定者は、例えば、救助されたなどの何らかの措置によって危機状況を免れたものとみなしたことになる。判定部３によって、被測定者が健常状態までに復帰したものと判定された場合、本発明の血糖測定装置は通常血糖測定モードＳ０１に移行する。
(Second risk level blood glucose measurement mode)
In the second risk level blood glucose measurement mode S08, the determination unit 3 first determines whether or not the state of the subject has returned to a normal state (S09 in FIG. 2). Whether or not it has returned to a healthy state is sufficient if at least the measured blood glucose level returns to a value greater than the first danger level blood glucose level. Preferably, it is a return to the normal range (daily fluctuation range), but the present invention is not limited to these. That is, the subject who is suspected of having a cerebral hypofunction is regarded as having escaped the crisis situation by some measure such as being rescued. When the determination unit 3 determines that the person to be measured has returned to the normal state, the blood glucose measurement device of the present invention shifts to the normal blood glucose measurement mode S01.
一方、判定部３にて測定血糖値が健常状態まで復帰しない場合、本発明の血糖測定装置は第２危険レベル血糖測定モードＳ０８を維持する。一定時間、例えば、１０〜３０分程度第２危険レベル血糖測定モードを維持するようであれば、再度判定部３から発信手段５を作動するべく信号を送信する（図２のＳ１０）。 On the other hand, when the measured blood glucose level does not return to the normal state in the determination unit 3, the blood glucose measurement device of the present invention maintains the second risk level blood glucose measurement mode S08. If the second risk level blood glucose measurement mode is to be maintained for a certain time, for example, about 10 to 30 minutes, a signal is transmitted again from the determination unit 3 to operate the transmission means 5 (S10 in FIG. 2).
本発明の血糖測定装置は、上述したように、被測定者自身で対応可能であるか否かにより、それぞれ対応した機構を作動する。このため、例えば、不用意に被測定者の血縁者等に被測定者が危険な状態であるという情報を送信することがない。したがって、被測定者の血縁者等の行動が制限される頻度が少なくなり、被測定者も周囲に迷惑をかけて申し訳ないという精神的ストレスが低減される。 As described above, the blood glucose measurement device of the present invention operates corresponding mechanisms depending on whether or not the measurement subject can cope with it. For this reason, for example, information that the measurement subject is in a dangerous state is not inadvertently transmitted to the relative of the measurement subject. Therefore, the frequency at which the actions of the relatives of the measurement subject are restricted is reduced, and the mental stress that the measurement subject also annoys the surroundings is reduced.
１ 測定部
２ 記憶部
２１ 第１危険レベル血糖値記憶メモリ
２２ 第２危険レベル血糖値記憶メモリ
３ 判定部
４ 通知手段
５ 発信手段
６ 入力部
７ 表示部
DESCRIPTION OF SYMBOLS 1 Measurement part 2 Memory | storage part 21 1st risk level blood glucose
Claims (1)
被測定者の血糖値を連続若しくは間欠的で測定する測定部と、
被測定者の第１危険レベル血糖値、並びに、被測定者の第２危険レベル血糖値を含む被測定者情報を記憶する記憶部と、
前記測定部で測定された血糖値と、前記記憶部に記憶された被測定者情報を参照することによって、被測定者が健常、第１危険レベル若しくは第２危険レベルであることを判定する判定部と、
前記判定部にて被測定者が第１危険レベルであると判定された時に、被測定者に第１危険レベルであることを通知する通知手段：及び
前記判定部にて被測定者が第２危険レベルであると判定された時に、被測定者が第２危険レベルであるという情報を発信する発信手段を備え、
前記判定部は、
（１）前記測定部で測定された血糖値が、前記記憶部から参照された第１危険レベルの血糖値に達した時に、被測定者が第１危険レベルである判定し、
（２）さらに、前記測定部で測定された血糖値が、第１危険レベル血糖値に達した後から一度も第１危険レベル血糖値以上に復帰せず、かつ前記記憶部から参照された第２危険レベルの血糖値に達した時に、被測定者が第２危険レベルであると判定する
ことを特徴とする血糖測定装置。 A device for continuously or intermittently measuring a subject's blood sugar level,
A measurement unit that continuously or intermittently measures the blood glucose level of the measurement subject;
A storage unit that stores measurement subject information including the first danger level blood glucose level of the measurement subject and the second danger level blood glucose level of the measurement subject;
Determination to determine whether the subject is healthy, at the first risk level, or at the second risk level by referring to the blood glucose level measured by the measurement unit and the subject information stored in the storage unit And
When the determination unit determines that the measured person is at the first danger level, a notification means for notifying the measured person that the measured person is at the first danger level; A transmission means for transmitting information that the measured person is at the second danger level when the danger level is determined to be;
The determination unit
(1) When the blood glucose level measured by the measurement unit reaches the blood glucose level of the first risk level referenced from the storage unit, the person to be measured is determined to be the first risk level;
(2) Furthermore, the blood glucose level measured by the measurement unit never returns to the first risk level blood glucose level or more once after reaching the first risk level blood glucose level, and is referred to from the storage unit. A blood glucose measuring device, wherein when the blood sugar level reaches a second risk level, the subject is determined to be at the second risk level.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006265690A JP4894439B2 (en) | 2006-09-28 | 2006-09-28 | Blood glucose measuring device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006265690A JP4894439B2 (en) | 2006-09-28 | 2006-09-28 | Blood glucose measuring device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008079993A JP2008079993A (en) | 2008-04-10 |
| JP4894439B2 true JP4894439B2 (en) | 2012-03-14 |
Family
ID=39351430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006265690A Active JP4894439B2 (en) | 2006-09-28 | 2006-09-28 | Blood glucose measuring device |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4894439B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6347881B1 (en) * | 2017-08-23 | 2018-06-27 | イセット株式会社 | Automatic notification device |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008253560A (en) * | 2007-04-05 | 2008-10-23 | Shinichi Yoshida | Device for detecting pseudohypoglycemia and issuing alarm |
| CN106377267B (en) * | 2016-02-26 | 2020-02-28 | 青岛华黎光电科技有限公司 | Device for detecting sweat of organism as physiological observation |
| JP6978144B1 (en) * | 2021-09-02 | 2021-12-08 | 株式会社Arblet | Information processing system, server, information processing method and program |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61259645A (en) * | 1985-05-14 | 1986-11-17 | シチズン時計株式会社 | Apparatus for detecting low blood sugar |
| JPH10328170A (en) * | 1997-05-29 | 1998-12-15 | Koji Akai | Blood sugar monitoring system |
| US20050027182A1 (en) * | 2001-12-27 | 2005-02-03 | Uzair Siddiqui | System for monitoring physiological characteristics |
| JP2003210418A (en) * | 2002-01-21 | 2003-07-29 | Yazaki Corp | Fatigue monitoring system of person at home |
| JP4320773B2 (en) * | 2003-02-14 | 2009-08-26 | マツダ株式会社 | Automotive health management system, automotive health management method, and automotive health management program |
| US20060001538A1 (en) * | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Methods of monitoring the concentration of an analyte |
-
2006
- 2006-09-28 JP JP2006265690A patent/JP4894439B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6347881B1 (en) * | 2017-08-23 | 2018-06-27 | イセット株式会社 | Automatic notification device |
| JP2019040291A (en) * | 2017-08-23 | 2019-03-14 | イセット株式会社 | Automatic notification device |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008079993A (en) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7175948B2 (en) | Systems and methods for quantifying and predicting smoking behavior | |
| US8636670B2 (en) | Circulatory monitoring systems and methods | |
| US8317776B2 (en) | Circulatory monitoring systems and methods | |
| US8125331B2 (en) | Health-related signaling via wearable items | |
| US8284046B2 (en) | Health-related signaling via wearable items | |
| US8130095B2 (en) | Health-related signaling via wearable items | |
| US8094009B2 (en) | Health-related signaling via wearable items | |
| US20230414102A1 (en) | Health-related signaling via wearable items | |
| US20100036269A1 (en) | Circulatory monitoring systems and methods | |
| US20090287101A1 (en) | Circulatory monitoring systems and methods | |
| US20090287191A1 (en) | Circulatory monitoring systems and methods | |
| US20090287109A1 (en) | Circulatory monitoring systems and methods | |
| US20100036209A1 (en) | Circulatory monitoring systems and methods | |
| US20100056873A1 (en) | Health-related signaling via wearable items | |
| JP2005501576A (en) | Patient monitoring configuration | |
| US20090292222A1 (en) | Circulatory monitoring systems and methods | |
| US20090292212A1 (en) | Circulatory monitoring systems and methods | |
| JP2021192302A (en) | Methods for quantification and prediction of smoking behavior | |
| US20090287093A1 (en) | Circulatory monitoring systems and methods | |
| JP4853207B2 (en) | Blood glucose measuring device | |
| US20100036268A1 (en) | Circulatory monitoring systems and methods | |
| JP2007000188A (en) | Medical support apparatus | |
| JP4894439B2 (en) | Blood glucose measuring device | |
| US20090287110A1 (en) | Circulatory monitoring systems and methods | |
| US20100036263A1 (en) | Circulatory monitoring systems and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090430 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111129 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4894439 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150106 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |